2003 – INTERESTING YEAR

There were two interesting events both related to CBD, that took place in 2003.

1. the US Federal Patent on CBD and other cannabinoid molecular particles

2. Application for trials with various CBD:THC extracts by GW Pharma was announced in:

Drugs in R & D:
2003 – Volume 4 – Issue 5 – pp 306-309
Adis R&D Profile

Is it possible this was a total coincidence? I find it difficult to believe. In this Drugs article, there was stated hope to have Sativex distributed way back in 2003.

I am not slamming GW at all; I think they are an incredibly forward thinking company. I am bringing this up as it is just one more example of the hypocrisy surrounding cannabis. Now, with more money coming into cannabis from everywhere, we had all better be very careful in potential “success” not to lose what we all have worked so hard for; legal, safe and effective cannabis medicines at compassionate prices.

Author
Allan Frankel, MD Dr Allan Frankel is one of the few physicians in the US who truly understands Cannabis as a medicine. All treatments suggested have been well studied. Every patient seen by Dr Frankel is given a personally created Treatment Plan created with the patient's specific issues defined. Plant medicine requires "tuning" of the dosing. Dr Frankel works with his patients thru a messaging portal. The use of this portal, allows quick and simple follow up contact with Dr Frankel. Patients are not charged for these messages, as this is how Dr Frankel has learned what he has learned. Follow up appointments in person or by phone/video are also available when needed

You Might Also Enjoy...

Rationing Health Care

With COVID, we have never been more aware of critical shortages of masks, ventilators, hospital beds, etc., all leading to rationing. In this BLOG, Dr Frankel, examines how rationing in our medical care is a much bigger problem than just face masks.

Cannabis May Prevent COVID-19 Infections

Early studies in both Israel and Canada show findings consistent with CBD's effect on COVID-19's ability to take hold in the lungs or the gastrointestinal tract. If the receptors are reduced, the viral infection and pulmonary toxicity should be reduced.